Biotechnology news

• BIO Spring IPCC Meeting: Special Offer for First Time In-House Attendees!

  06-03-2017 22:24
  
  Are you a patent practitioner at a biotech company?
  Is your in-house IP group small, or are you perhaps the only “IP person” in your company?
  Would you like more opportunities to connect with similarly-situated in-house colleagues, get updates and analysis on patent law developments, share best practices, and participate in policy discussions that affect our industry?
  Have you never attended the BIO IP Counsels Committee Conference, but always wanted to?
  BIO wants you, and can make i
  
  Read more

• Novogen Wins $2.28M Grant for Anti-Tropomyosin Therapeutics Collaboration

  06-03-2017 16:35
  Novogen won an Aus$3 million (approximately $2.28 million) grant from the Australian government to lead a collaboration focused on next-generation anti-tropomyosin therapeutics against cancer. Novogen will work with collaborators at the University of New South Wales (UNSW) and with contract research organization ICP Firefly. The project is outside the scope of Novogen’s existing preclinical anti-tropomyosin candidate Anisina™ (ATM-350).The grant has been awarded under the Australian
  
  Read more

• Opioid Acts Only on Hurt Tissues, Skips Side Effects

  06-03-2017 16:23
  Opioids, like sledgehammers, are powerful but blunt tools. When they are used to flatten pain, opioids may give other things a pounding, too. The problem is conventional opioids act on inflamed or damaged tissues as well as healthy tissues. Consequently, while opioids may relieve pain, they may also cause serious side effects, such as drowsiness, nausea, constipation, and dependency—and in some cases, respiratory arrest.In hopes of finding a way to craft finer painkilling tools, scientists
  
  Read more

• Vaxess Wins $6M in Gates Foundation Grants for Vaccine Delivery Platform

  06-03-2017 15:00
  Vaxess Technologies said today it has won two grants totaling $6 million from the Bill & Melinda Gates Foundation toward developing the company’s platform for delivering inactivated polio (IPV) and live attenuated measles rubella (MR) vaccines.The vaccines will use Vaxess’ MIMIX™ sustained-release microneedle patch technology, designed to deliver vaccines as well as immunotherapies by application to the skin rather than the traditional needle-and-syringe approach. MIMI
  
  Read more

• Advertisement

• Vertex Looks to Expand CF Pipeline with Concert's Deuterated Ivacaftor Candidate

  06-03-2017 14:30
  Vertex Pharmaceuticals agreed a potentially $250 million deal to acquire global rights to Concert Pharmaceuticals’ mid-stage cystic fibrosis (CF) therapy candidate CTP-656. Under terms of the proposed deal, Vertex would pay Concert $160 million upfront and potentially another $90 million in milestones, dependent on regulatory approval of CTP-656 in the U.S. and reimbursement in the U.K., Germany, or France. Vertex would also acquire rights to Concert’s other CF research and preclinic
  
  Read more

• CRISPETa Software Developed to Efficiently Delete Noncoding DNA Regions

  06-03-2017 14:29
  Scientists at the Computational Biology of RNA Processing laboratory of the Centre for Genomic Regulation (CRG) in Barcelona, Spain recently created a tool based on CRISPR/Cas9 called DECKO, which can be used to delete any desired piece of noncoding DNA. CRISPR/Cas9 is composed of two components: a molecular barcode, called single guide RNA (sgRNA), which is designed by researchers to recognize one precise location in the genome, and the Cas9 protein, which binds to a structured loop in the
  
  Read more

Follow @Biotech_News_AU on Twitter!